[go: up one dir, main page]

MX2018012904A - Uso de beta-agonistas del receptor de la hormona tiroidea. - Google Patents

Uso de beta-agonistas del receptor de la hormona tiroidea.

Info

Publication number
MX2018012904A
MX2018012904A MX2018012904A MX2018012904A MX2018012904A MX 2018012904 A MX2018012904 A MX 2018012904A MX 2018012904 A MX2018012904 A MX 2018012904A MX 2018012904 A MX2018012904 A MX 2018012904A MX 2018012904 A MX2018012904 A MX 2018012904A
Authority
MX
Mexico
Prior art keywords
agonists
thyroid beta
thyroid
beta
treating
Prior art date
Application number
MX2018012904A
Other languages
English (en)
Inventor
Lian Brian
Hanley Rochelle
Dinerman Misha
Original Assignee
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viking Therapeutics Inc filed Critical Viking Therapeutics Inc
Publication of MX2018012904A publication Critical patent/MX2018012904A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a métodos útiles para tratar la adrenoleucodistrofia enlazada a X.
MX2018012904A 2016-04-22 2017-04-24 Uso de beta-agonistas del receptor de la hormona tiroidea. MX2018012904A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662326431P 2016-04-22 2016-04-22
PCT/US2017/029102 WO2017185083A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (1)

Publication Number Publication Date
MX2018012904A true MX2018012904A (es) 2019-01-31

Family

ID=60117062

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012904A MX2018012904A (es) 2016-04-22 2017-04-24 Uso de beta-agonistas del receptor de la hormona tiroidea.

Country Status (10)

Country Link
US (1) US20190134069A1 (es)
EP (1) EP3445372A4 (es)
JP (1) JP2019515915A (es)
KR (1) KR102407053B1 (es)
CN (3) CN110200978B (es)
AU (2) AU2017252122B2 (es)
BR (1) BR112018071559B1 (es)
CA (1) CA3021677C (es)
MX (1) MX2018012904A (es)
WO (1) WO2017185083A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102407059B1 (ko) 2016-04-22 2022-06-10 바이킹 테라퓨틱스 인코포레이티드 갑상선 베타-작용제의 사용
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof
JP2025520449A (ja) * 2022-06-15 2025-07-03 バイキング セラピューティクス，インコーポレーテッド Ｘ－ａｌｄ治療のための甲状腺ベータ作動薬投与計画

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
DE69115694T2 (de) 1990-06-13 1996-10-17 Arnold Newton Mass. Glazier Phosphorylierte prodrugs
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
EP0632048B1 (en) 1993-06-29 2001-03-21 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
AU2004263149B2 (en) 2003-08-07 2010-08-19 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP2007524656A (ja) * 2003-10-23 2007-08-30 セルジーン・コーポレーション 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
BRPI0518616A (pt) * 2004-12-08 2008-01-15 Sirion Therapeutics Inc métodos para tratar doenças relacionadas com retinol, degeneração ou distrofia macular e diabetes tipo i ou tipo ii
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
JPWO2007097289A1 (ja) * 2006-02-20 2009-07-16 武田薬品工業株式会社 新規医薬
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
CA2808307C (en) * 2010-08-16 2022-06-21 Allergan, Inc. Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP2018510849A (ja) * 2015-02-20 2018-04-19 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ ソベチロムの誘導体
CN108602613B (zh) * 2016-02-29 2020-06-16 菲利普莫里斯生产公司 铰接盖容器和坯料
AU2017267734B2 (en) * 2016-05-18 2021-09-09 Oregon Health & Science University Derivatives of sobetirome

Also Published As

Publication number Publication date
EP3445372A4 (en) 2020-03-25
BR112018071559B1 (pt) 2024-02-06
WO2017185083A1 (en) 2017-10-26
KR20190017748A (ko) 2019-02-20
CA3021677C (en) 2024-11-12
CN109641003A (zh) 2019-04-16
AU2023202321A1 (en) 2023-05-11
CA3021677A1 (en) 2017-10-26
EP3445372A1 (en) 2019-02-27
KR102407053B1 (ko) 2022-06-10
CN110200978A (zh) 2019-09-06
AU2017252122A1 (en) 2018-11-15
US20190134069A1 (en) 2019-05-09
JP2019515915A (ja) 2019-06-13
AU2023202321B2 (en) 2025-04-24
AU2017252122B2 (en) 2023-02-09
CN110200978B (zh) 2023-10-31
BR112018071559A2 (pt) 2019-05-14
CN113730421A (zh) 2021-12-03

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
GB2556286A (en) Programmable voltage reference
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2017001981A (es) Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
MX2017005797A (es) Receptores quimericos de antigeno anti-cldn y metodos de uso.
MX2016009858A (es) Fusiones anti proteína convertasa subtilisina/kexina tipo 9 (anti-pcsk9)n péptido 1 similar a glucagón (glp-1) y métodos de uso.
MX2020012893A (es) Formulaciones de proteinas.
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
PH12017500602A1 (en) Methods for treating ocular conditions
SG11201703991PA (en) System for the generation of call advance data
MX2018012900A (es) Uso de beta-agonistas del receptor de la hormona tiroidea.
MX2018012904A (es) Uso de beta-agonistas del receptor de la hormona tiroidea.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3094347A4 (en) Methods for enhancing the delivery of active agents
EP3285764A4 (en) Methods for treating cryptosporidiosis using triazolopyridazines
MX2016009541A (es) Metodo para tratar vajilla.
WO2016040313A3 (en) Methods of treating cancer comprising administering a ppar-gamma agonist